PELL BIO-MED TECHNOLOGY CO., LTD.
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
1. ADSC Therapy
2. CIK Therapy
3. DC-CIK Therapy
2. CIK Therapy
3. DC-CIK Therapy
Founded Year
2017
Unified Business No.
59229683
Status
Active
Number of Employees
0
Total Paid-in
Capital
586,545,500 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Innovation Board(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
In March 2017, PELL Bio-Med Technology Co. Ltd. was founded in Zuoying District, Kaohsiung City, Taiwan. Specializing in the development of cell culture and clinical applications of cell therapy, PELL embarked on its journey. Initially focused on producing autologous immune cells and adipose-derived stem cells, PELL's growth led to the establishment of its main headquarter in Taipei City's Neihu Science Park in May 2019, with Kaohsiung serving as a branch office. At the same time, PELL continued fostering collaborations with various research units and medical institutions, domestic and abroad, advancing its innovative journey guided by its core values of health, care, precision, and professionalism.
